

IN THE CIRCUIT COURT OF THE CITY OF RICHMOND


COMMONWEALTH OF VIRGINIA, *EX REL.*
MARK R. HERRING, ATTORNEY GENERAL,

Plaintiff,

v.

WYETH PHARMACEUTICALS INC.,

Defendant.



Case No. _____

COMPLAINT

1. The Plaintiff, Commonwealth of Virginia (the "Commonwealth"), by, through, and at the relation of the Attorney General, Mark R. Herring ("Attorney General") petitions this Court to declare that the activities in which the Defendant, Wyeth Pharmaceuticals Inc., has engaged constitute violations of the Virginia Consumer Protection Act ("VCPA"), Virginia Code § 59.1-196 through 59.1-207. The Commonwealth prays that this Court grant the relief requested in this Complaint and states the following in support thereof.

JURISDICTION AND VENUE

2. The Circuit Court of the City of Richmond has authority to entertain this action and to grant the relief requested herein pursuant to Virginia Code §§ 8.01-620, 17.1-513, and 59.1-203.

3. Venue is preferred in this Court pursuant to Virginia Code § 8.01-261(15)(c) because some or all of the acts to be enjoined are, or were, being done in the City of Richmond. Venue is permissible in this Court pursuant to § 8.01-262(3) and (4) because

Defendant regularly conducts substantial business activity within the City of Richmond and the cause of action arose, in part, in the City of Richmond.

PARTIES

4. The Plaintiff is the Commonwealth by, through, and at the relation of the Attorney General.

5. Defendant Wyeth Pharmaceuticals Inc. is a wholly owned subsidiary of Pfizer Inc., a Delaware corporation with its principal place of business at 235 East 42nd Street, New York, NY 10017. At all relevant times, Wyeth did business in Virginia by, among other things, selling and promoting the prescription drug Rapamune®.

FACTS

I. BACKGROUND

6. With certain limited exceptions not relevant here, a drug may not be distributed in interstate commerce without FDA approval.

7. To gain FDA approval, data from adequate and well-controlled clinical trials must demonstrate that the drug is safe and effective for a particular use.

8. As part of the approval process, the FDA must approve the drug's labeling which is required to set forth detailed information about the drug, including the approved medical conditions of use, dosages, and patient populations.

9. Once the FDA has found a drug to be safe and effective for a particular use and approved it for that use, doctors are free to exercise their medical judgment to prescribe the drug for other, unapproved (or "off-label") uses. However, manufacturers are proscribed by federal law from promoting the drug for off-label uses.

10. Rapamune (sirolimus) is an immunosuppressant drug that was approved by the

FDA in 1999 as an “adjunct” drug in combination with cyclosporine and steroids to prevent rejection of the transplanted kidney. It is not approved for use by any other type of organ transplant patient. Nor is it approved for combination with other drugs.

11. Rapamune is only approved as “de-novo” treatment—meaning for use immediately after a transplant. It is not approved for “conversion”—meaning switching to another immunosuppressant sometime after the transplant.

12. In 2002, FDA required a “black box warning” to be added to Rapamune’s labeling. This warning informed prescribers and patients that Rapamune use by liver transplant patients is associated with serious risks, including graft loss and death.

13. In 2003, FDA required another “black box warning” to be added to Rapamune’s labeling. This time, to caution that Rapamune use by lung transplant patients is associated with serious risks, including death.

14. In 2007, another warning was added regarding a serious side effect called proteinuria (protein in urine).

15. In June, 2009, yet another warning was added based on the results of a Wyeth study that suggested that liver transplant patients prescribed Rapamune experience “significantly higher” organ rejection than patients treated with alternative immunosuppressant drugs.

II. ALLEGATIONS RELATING TO DEFENDANT’S MARKETING AND PROMOTION OF RAPAMUNE

16. Despite Rapamune’s limited approval for use in kidney (renal) transplant only, and despite black box warnings relating to use in lung and liver transplants, Wyeth promoted Rapamune off-label for non-renal transplants patients such as liver, heart, pancreas, islet (pancreas cells), and lung transplant patients.

17. Wyeth also promoted Rapamune off-label using a “conversion” protocol (switching a patient to Rapamune after de novo use of a different transplant rejection drug).

18. Wyeth also promoted Rapamune off-label for use after kidney transplant in combination with drugs other than indicated in the product’s FDA approved labeling.

CAUSE OF ACTION

Count I – Violation of Virginia Code § 59.1-200(A)(5)

19. Plaintiff realleges and incorporates by reference herein each and every allegation contained in the preceding Paragraphs 1 through 18.

20. Virginia Code § 59.1-200(A)(5) prohibits a supplier from misrepresenting that goods or services have certain quantities, characteristics, ingredients, uses, or benefits in connection with a consumer transaction.

21. Defendant, in the course of engaging in the development, manufacture, promotion, sales, and interstate distribution of the prescription drug Rapamune®, has engaged in deceptive or misleading practices that are unlawful under § 59.1-200(A)(5) by representing that Rapamune® has quantities, characteristics, ingredients, uses, or benefits that it does not have.

22. Defendant willfully committed the violations of § 59.1-200(A)(5) described herein.

23. Individual consumers suffered monetary damages and other losses as a result of the aforesaid violations by Defendant.

PRAYER FOR RELIEF

WHEREFORE, Plaintiff, Commonwealth of Virginia, respectfully requests that

this Court:

- A. Permanently enjoin and restrain Defendant, its agents, employees, and all other persons and entities, corporate or otherwise, in active concert or participation with any of them, from engaging in deceptive or misleading conduct, acts, or practices which violate the VCPA in the promotion and marketing of its prescription drug Rapamune® pursuant to Virginia Code § 59.1-203(A);
- B. Order Defendant to pay civil penalties of up to \$2,500 for each and every willful violation of the VCPA pursuant to Virginia Code § 59.1-206(A);
- C. Order Defendant to pay costs incurred by the Commonwealth in investigating and preparing the case, not to exceed \$1,000 per violation, and reasonable attorneys' fees pursuant to Virginia Code § 59.1-206(C); and
- D. Grant Plaintiff such other and further relief as the Court deems equitable and proper.

COMMONWEALTH OF VIRGINIA,
EX REL. MARK R. HERRING,
ATTORNEY GENERAL

By: 
Matthew R. Hull

Mark R. Herring
Attorney General

Cynthia E. Hudson
Chief Deputy Attorney General

Rhodes B. Ritenour
Deputy Attorney General

David B. Irvin (VSB # 23927)
Senior Assistant Attorney General

Matthew R. Hull (VSB # 80500)
Assistant Attorney General

Office of the Attorney General of Virginia
Consumer Protection Section
900 East Main Street
Richmond, Virginia 23219
Telephone: (804) 371-2084
Fax: (804) 786-0122